Last Price
0.003
Today's Change
0.00 (0.00%)
Day's Change
0.003 - 0.003
Trading Volume
1,733,257
Overview
Market Cap
3 Million
Shares Outstanding
1 Billion
Avg Volume
2,169,487
Avg Price (50 Days)
0.00
Avg Price (200 Days)
0.01
PE Ratio
-0.30
EPS
-0.01
Earnings Announcement
22-Aug-2025
Previous Close
0.00
Open
0.00
Day's Range
0.003 - 0.003
Year Range
0.002 - 0.024
Trading Volume
1,733,257
Price Change Highlight
1 Day Change
0.00%
5 Day Change
20.00%
1 Month Change
50.00%
3 Month Change
-28.57%
6 Month Change
-81.25%
Ytd Change
-83.33%
1 Year Change
-86.36%
3 Year Change
-94.12%
5 Year Change
-97.06%
10 Year Change
-98.86%
Max Change
-98.86%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
Discussions
Be the first to like this.
Showing 0 of 0 comments
Post a Comment
Latest Videos
![[New IPO] Oxford Innotech Berhad, a precision engineering and automation solutions provider, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1208/Thumbnail_.png)
![[New IPO] Enproserve Group Berhad, a plant maintenance specialist in the O&G sector, plans to list on the Ace Market!](https://mqac.i3investor.com/img/video_thumbnail/1198/Thumbnail__(10).png)
Apps
Top Articles
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
{uid}
{comment}
Just now